Patrys Limited PAB

ASX · Australia · Health Technology

AUD 0.03300.00 (0.00%)

Market open· Oct 1, 2026, 3:23 AM UTC· AUD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Patrys Limited PAB

ASX · Australia · Health Technology

AUD 0.03300.00 (0.00%)

Market open· Oct 1, 2026, 3:23 AM UTC· AUD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

+22.22% · 6MFull-screen chart

Open AUD 0.0330High AUD 0.0330Low AUD 0.0330Close AUD 0.0330Volume 141.87K

Oct 1, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: AUD 0.0330
Day range: AUD 0.0330 – AUD 0.0330
52-week range: AUD 0.0250 – AUD 0.0520
Volume: 141.87K
Market cap: AUD 20.92M
Avg. volume (1Y): 700.17K

Performance

1 week

+3.12%

1 month

+6.45%

3 months

-15.38%

6 months

+26.92%

Year to date

+22.22%

1 year

-5.71%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: Australia
Exchange: ASX
Shares outstanding: 674.85M
ISIN: AU000000PAB9
Beta: 2.45

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceMar 17, 2026

BioCina Initiates Comprehensive Manufacturing Program for Patrys' Proprietary Injectable Therapeutic to Alleviate Delirium

BioCina Pty Ltd., a global end-to-end Contract Development and Manufacturing Organisation (CDMO) announced it has initiated a comprehensive CMC (Chemistry, Manufacturing, and Controls) program for the advancement of RLS-2201, a proprietary injectable formulation of Quetiapine being developed by Patrys Ltd (ASX: PAB) for the acute treatment of delirium in intensive care settings.

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.